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Introduction
Cancer is characterized by uncontrolled cell proliferation be-
cause of genetic and epigenetic abnormalities.[1] Epigenetics
refers to the heritable changes in gene expression caused by
histone or DNA modifications as opposed to alterations in the
DNA primary sequence.[2] Unlike genetic changes, epigenetic
changes are potentially reversible through modulation of epi-
genetic machinery which lends itself towards therapeutic ma-
nipulation. The appreciation that cancer can be driven above
the DNA level has created an opportunity to develop cancer
therapeutics that modulate aberrant epigenetic states charac-
teristic of tumor cells.
Histone modifications regulate the local chromatin architec-
ture surrounding DNA sequences and are important epigenetic
regulators of cell growth and proliferation.[3] Histone acetyla-
tion is a common epigenetic modification and is controlled by
histone acetyltransferases and deacetylases. Histone deace-
tylases (HDACs) are responsible for the deacetylation of histo-
nes which leads to compaction of the surrounding DNA re-
gions and repression of gene transcription. Aberrant HDAC ac-
tivity has been associated with numerous cancers, making
HDAC inhibition a promising therapeutic target.[4] HDAC inhibi-
tion induces apoptosis in malignant cells through various
mechanisms, including alterations in cell cycle regulation and
activation of oxidative stress pathways.
There are four classes of HDACs: class I (HDAC1, 2, 3, and 8),
class II (HDAC4, 5, 6, 7, 9, and 10), and class IV (HDAC11) repre-
sent Zn2+-dependent amidohydrolases, whereas class III is
composed of the mechanistically distinct NAD+-dependent sir-
tuins.[5] Class I, II, and IV HDAC inhibitors (HDACi) consist of
a capping group that is exposed to the environment, an alkyl
linker that is surrounded by a hydrophobic tunnel, and
a metal-binding moiety that is buried in the protein active
site.[6] Because the metal-binding moiety, which is critical for
HDACi activity, is structurally similar across Class I, II, and IV
HDACi, modifications of this structural element can be applied
to many HDACi.
Dendrimers are branched, synthetic macromolecules with
controllable chemical topology which have been used for
a broad range of biomedical applications, including drug deliv-
ery, gene transfection, and tissue engineering.[7] Our early stud-
ies demonstrated that folic acid (FA) conjugated to a genera-
tion 5 (G5) polyamidoamine (PAMAM) dendrimer could target
the folate receptor (FR) on cancer cells to deliver therapeutics
in vitro and in vivo.[8] These studies demonstrated that target-
ing cancer cells greatly enhanced the efficacy and reduced the
toxicity of the dendrimer therapeutics compared with thera-
peutics alone. Building on these studies, we have improved
the synthetic approach by using the highly efficient copper-
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catalyzed azide–alkyne 1, 3-dipo-
lar cycloaddition (CuAAC) as well
as exploring different targeting
ligands and therapeutics to opti-
mize the efficacy of targeted
drug delivery.[9] In this report, we
describe the synthesis and bio-
logical evaluation of tumor-spe-
cific dendrimer–HDACi conju-
gates. We demonstrate the cell
specificity and efficacy of dendri-
mer–HDACi conjugates in
a human epithelial cancer cell
model and also show that the tumor-specific HDACi have no
effects on tumor-associated macrophages.
Results and Discussion
Synthesis and characterization of linker-modified suberoyl-
anilide hydroxamic acid (SAHA) compounds and dendrimer–
SAHA conjugates
In this report, we used suberoylanilide hydroxamic acid (SAHA)
as a representative HDACi.[10] SAHA has antitumor activity and
structural elements that are shared by many Zn-dependent
HDACi. To conjugate SAHA to the dendrimer scaffold, we
modified SAHA with an azido-linker through the hydroxamic
acid group. The modified SAHA was attached to the alkyne-
modified G5 PAMAM dendrimer scaffold using the CuAAC reac-
tion. Based on our prior work on cleavable linkers, we sought
to evaluate the effects of two different linkages, an ester and
an amide, on the functional properties of SAHA.[7b] The linker-
modified SAHA compounds were synthesized as shown in
Scheme 1. We modified SAHA with an azido-linker through
either an ester bond (SAHA-eAzide 1) or an amide bond
(SAHA-aAzide 2). The control dendrimer–HDACi conjugate (G5-
eSAHA-Alkyne 5) and targeted dendrimer–HDACi conjugate
(G5-FA-eSAHA-Alkyne 6) (Scheme 2) were synthesized using
the CuAAC reaction of SAHA-eAzide 1 with the corresponding
alkyne-modified dendrimers 3 and 4, respectively (Scheme 3).
The conjugates and intermediates were analyzed by matrix-
assisted laser desorption ionization/time-of-flight mass spec-
trometry (MALDI-TOF MS), high-performance liquid chromatog-
raphy (HPLC), and NMR as we have previously described.[11]
The number of ligands (FA and SAHA) attached to the dendri-
mer scaffold was obtained from the integration of the methyl
protons of the terminal acetyl groups to the aromatic protons
on the conjugated ligands. The number of acetyl groups per
dendrimer was determined by computing the total number of
end groups from the number average molecular weight from
gel permeation chromatography (GPC) and potentiometric ti-
tration data for G5-NH2 (100%) as we have previously de-
scribed.[12] The total number of end groups was applied to the
ratio of primary amines to acetyl groups, obtained from the
1H NMR of the partially acetylated dendrimer, to compute the
average number of acetyl groups per dendrimer.
Biological evaluation of linker-modified SAHA compounds
To evaluate the functionality of the linker-modified SAHA com-
pounds, we used the annexin V/7-aminoactinomycin D (An/
7AAD) apoptosis assay and the folate-receptor-overexpressing
KB human cancer cell line. KB cells were incubated with
100 nm of the linker-modified SAHA compounds 1 or 2 or free
SAHA. After 24 h, the cells treated with the ester-linker-modi-
fied SAHA (SAHA-eAzide 1) and free SAHA had evidence of
apoptosis, while the amide-linker-modified SAHA (SAHA-aAzide
2) did not show any evidence of apoptosis (Figure 1). To verify
that the KB cell apoptosis was due to alteration of histones,
Scheme 1. Synthesis of SAHA-eAzide 1 and SAHA-aAzide 2. Reagents and conditions : a) 5-azidopentanoic acid,
CMPI, DMAP, DMF, rt, 6 h, 14% (1), 20% (2).
Figure 1. Biological evaluation of linker-modified SAHA. a) Apoptosis index
demonstrating apoptosis induction with free SAHA and the ester-modified
SAHA. The amide-modified SAHA did not demonstrate any evidence of
apoptosis at the time points and concentrations tested. KB cells were incu-
bated with 100 nm of the linker-modified SAHA compounds and free SAHA
for 24 h. Values represent the mean  S.E.M. for n=3 independent experi-
ments. b) Protein immunoblots demonstrate that both free SAHA and
eSAHA induce hyperacetylation of histones consistent with their known epi-
genetic mechanism of action. In agreement with the apoptosis data, the
amide-modified SAHA compound did not demonstrate any hyperacetylation
of histones. KB cells were incubated with 10 mm of the SAHA compounds
2 h and cell lysates were collected. Total ERK was used as the protein load-
ing control.
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we probed for histone acetylation using protein immunoblot-
ting. We found that free SAHA and the SAHA-eAzide 1 not
only increased apoptosis, but also induced hyperacetylation of
histones confirming that SAHA-eAzide 1 was still active
(Figure 1). In contrast, the amide-modified SAHA (SAHA-
aAzide 2) did not induce apoptosis or histone hyperacetylation,
suggesting that this modification inactivated the SAHA mole-
cule.
Tumor-specific uptake of dendrimer–SAHA conjugates
Because only the SAHA-eAzide 1 demonstrated therapeutic ef-
ficacy, further evaluations were conducted using only the
ester-modified SAHA compound. Next, we wanted to compare
the cell specificity of the tumor-specific dendrimer–SAHA con-
jugates. We and others have shown that FA-functionalized
dendrimers internalize through the FR in vitro and in vivo.[14]
Using our recently described in situ click reporter strategy, we
monitored the uptake of the FA-targeted and nontargeted
control dendrimer–SAHA conjugates by flow cytometry.[14b]
This strategy allows us to track dendrimer therapeutics after
they have been delivered to cells by using CuAAC to conjugate
fluorescent reporters in situ. We incubated G5-FA-eSAHA-
Alkyne 6 and the nontargeted control G5-eSAHA-Alkyne 5 with
KB cells for one hour at 37 8C. After incubation, the cells were
washed and processed, and Alexa Fluor 647-azide (AF647) was
conjugated to the internalized dendrimer conjugates using the
CuAAC reaction as we have previously described.[14b] The G5-
FA-eSAHA-Alkyne 6 demonstrated a dose-dependent uptake
into KB cells while the nontargeted G5-eSAHA-Alkyne 5 did
not demonstrate any uptake (Figure 2). Importantly, the uptake
of G5-FA-eSAHA-Alkyne 6 could be blocked by pretreatment
with 100 mm FA, confirming the FR-specificity of the tumor-tar-
geted dendrimer–HDACi (Figure 2). To further confirm the cell
Scheme 2. Structures of PAMAM G5 dendrimer conjugates 5 and 6.
Scheme 3. Synthesis of PAMAM G5 dendrimer conjugates 5 and 6. Reagents
and conditions : a) 1) CuSO4, sodium ascorbate, SAHA-eAzide 1, under N2,
o/n, 2) glycidol, rt, 6 h, 84% (5), 85% (6).
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specificity of the dendrimer conjugates, we used our in situ
click reporter strategy and confocal microscopy to demon-
strate the FR-dependent uptake of the targeted-dendrimer
SAHA conjugates. KB cells were treated as described above for
one hour. After incubation, the KB cells were processed, and
Alexa Fluor 555-azide (AF555) was conjugated to the internal-
ized dendrimer conjugates using the CuAAC reaction. The G5-
FA-eSAHA-Alkyne 6 had significantly more uptake at one hour
compared with the nontargeted G5-eSAHA-Alkyne 5 (Figure 2).
Biological evaluation of dendrimer–SAHA conjugates
After confirming the activity of the ester-modified SAHA com-
pound and the cell specificity of the G5-FA-eSAHA-Alkyne 6,
we then evaluated the therapeutic efficacy of the dendrimer–
SAHA conjugates. The activity of HDACi depends upon its hy-
droxamic acid moiety and its ability to block zinc-dependent
histone deacetylases. Based on previous studies, we hypothe-
sized that the G5-FA-eSAHA-Alkyne 6 conjugates would target
FR-overexpressing cancer cells, internalize, and hydrolyze in
the endosome, allowing free SAHA to inhibit histone deacety-
lases and to induce apoptosis. We evaluated the cytotoxicity of
the dendrimer–SAHA conjugates 5 and 6 at five days. As ex-
pected, the G5-FA-eSAHA-Alkyne 6 was more cytotoxic com-
pared with the nontargeted G5-eSAHA-Alkyne 5 (Figure 2).
One of the advantages of tumor-specific therapeutics is that
many cancer drugs can also affect the immune system, reduc-
ing its ability to combat tumor initiation and progression. Mac-
rophages contribute a large proportion of the cells in the
tumor microenvironment and increased numbers are associat-
ed with a worse prognosis.[15] Several studies have shown that
HDACi are immunosuppressive through their effects on macro-
phages.[16] Because of these macrophage effects, avoidance of
HDAC inhibition in macrophages is desirable. To evaluate the
capacity of the tumor-specific HDACi to avoid clearance and
effects on macrophages, we examined the cytotoxic effects of
free SAHA and the dendrimer–SAHA conjugates in the macro-
phage cell model RAW264.7. RAW264.7 cells were treated with
free SAHA and the dendrimer–SAHA conjugates for 72 hours
and evaluated for evidence of apoptosis using the An/7AAD
assay mentioned above. At 72 hours, free SAHA induced apop-
tosis in RAW264.7 cells, while the dendrimer–SAHA conjugates
had no effect, further confirming the cell specificity of the
tumor-specific dendrimer–SAHA conjugates (Figure 3).
In this study, we used the CuAAC reaction to engineer
tumor-specific dendrimer HDACi and evaluated their function-
ality in a cancer cell model. To our knowledge, this is the first
description of a tumor-specific HDACi—an approach that has
the potential to greatly improve the efficacy and reduce the
toxicities associated with this class of epigenetic therapeutics.
Additionally, we evaluated the functional effects of modifying
the metal-binding domain of HDACi with different linkers.
These results provide important insights on HDACi that will
help inform the rational optimization of this promising class of
therapeutics.
Most HDACi are composed of three functional elements:
a capping group, a carbon linker, and a metal-binding domain.
Figure 2. Biological evaluation of the dendrimer SAHA conjugates. a) Mean
fluorescence intensity (MFI) demonstrates concentration-dependent uptake
of the G5-FA-eSAHA compared to other conjugates. Pretreatment of KB cells
with free FA blocked this uptake confirming the FR specificity of the target-
ed dendrimer conjugates. KB cells were incubated with dendrimer SAHA
conjugates for 1 h and analyzed by flow cytometry for cell-specific uptake.
Values represent the mean  S.E.M. for n=3 independent experiments.
b) Confocal images using the in situ click detection methodology confirm
the cell specificity of the FA-targeted dendrimer conjugates (punctate, green
cytoplasmic signal ; left panel) compared with the nontargeted controls (no
cytoplasmic signal ; right panel). KB cells were incubated with 100 nm of the
dendrimer SAHA conjugates for 1 h and subsequently analyzed using confo-
cal microscopy. c) KB cells treated with the targeted G5-FA-eSAHA showed
significantly greater levels of apoptosis than KB cells treated with the non-
targeted G5-eSAHA. KB cells were treated with dendrimer–SAHA conjugates
for 5 d and assessed for apoptosis using the annexin/7AAD assay. Values rep-
resent the mean  S.E.M. for n=3 independent experiments.
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We have previously demonstrated that a cleavable linker to
attach a therapeutic to the dendrimer scaffold increases the ef-
ficacy of the therapeutic once it is delivered to the target
cell.[7b] Building on these studies, we chose to modify the hy-
droxamic acid metal-binding domain for the dual purpose of
providing a chemical handle to conjugate the HDACi to the
dendrimer scaffold, as well as to inactivate the HDACi while it
is attached to the dendrimer scaffold. As expected, the stable
amide-linker modified HDACi was nonfunctional ; however, the
ester-linker modified HDACi was functional and led to hyper-
acetylation of histones and triggered apoptosis.
Some of the biggest challenges facing traditional HDACi are
limitations in efficacy and toxicities, both of which are at least
partially due to the lack of site-specific delivery of HDACi to
the desired biological targets. We and others have used bio-
logical and synthetic ligands with PAMAM dendrimer scaffolds
to target drugs to diseased cells and tissues. This approach not
only improves the pharmacologic properties of the therapeutic
by enhancing its circulating half-life and decreasing the off-
target effects, but this approach also increases the local con-
centration of the therapeutic in diseased cells, further enhanc-
ing the therapeutic efficacy. As our molecular understanding of
cancer evolves, the toolbox of receptor–ligand combinations
that can be used to facilitate tumor-specific interactions will
expand, further improving our ability to develop site-specific
therapeutics to treat cancer and other diseases.
Conclusions
In summary, we have developed a tumor-specific histone de-
acetylase inhibitor (HDACi) using a polyamidoamine (PAMAM)
dendrimer scaffold and a representative HDACi that shows cell
specificity and therapeutic efficacy in a cancer cell model. Spe-
cifically, we have shown that 1) click chemistry can be used to
efficiently functionalize tumor-specific dendrimer scaffolds with
HDACi, 2) the ester-modified HDACi compounds and the ester-
linked dendrimer–HDACi conjugates lead to increased histone
acetylation and apoptosis, and 3) the tumor-specific HDACi
have no effects on tumor-associated macrophages thereby in-
creasing their therapeutic efficacy on cancer cells. Further stud-
ies are ongoing to evaluate the efficacy of this tumor-specific
epigenetic therapeutic in vivo.
Experimental Section
1H NMR spectra were obtained using a Varian Inova 500 MHz (Palo
Alto, USA). MALDI-TOF mass spectra were recorded on a PE Biosys-
tems Voyager System 6050 (Waltham, USA), using 2,5-dihydroxy-
benzoic acid (DHB) as the matrix. Electrospray ionization mass
spectra (ESI-MS) were recorded using a Micromass Quattro II Elec-
tronic HPLC/MS/MS mass spectrometer (Waters, Milford, USA).
Materials: All solvents and chemicals were of reagent grade quali-
ty, purchased from Sigma–Aldrich (St. Louis, USA), and used with-
out further purification unless otherwise noted. Thin-layer chroma-
tography (TLC) and column chromatography were performed with
25 DC-Plastikfolien Kieselgel 60 F254 (Merck, Kenilworth, USA), and
Baxter silica gel 60 æ (230–400 mesh, Baxter International, Deer-
field, USA), respectively.
Synthesis of G5-NHAc-Alkyne 3 and G5-NHAc-FA-Alkyne 4. Com-
pounds 3 and 4 were synthesized as we have previously de-
scribed.[9,11,13] G5-NHAc-Alkyne 3 was obtained as a white solid;
MALDI-TOF MS m/z : 32774 [M]+ ; the 1H NMR-integration-deter-
mined mean number of acetyl groups per dendrimer is 80.1, and
the mean number of alkyne ligands per dendrimer is 12.3. G5-
NHAc-FA-Alkyne 4 was obtained as a brown solid; MALDI-TOF MS
m/z : 33059[M]+ ; the 1H NMR-integration-determined mean number
of FA per dendrimer is 3.5, and the mean number of free alkyne
ligands per dendrimer is 8.8.
Synthesis of N1-((5-azidopentanoyl)oxy)-N8-phenyloctanediamide
(SAHA-eAzide, 1) and N1-(5-azidopentanoyl)-N1-hydroxy-N8-phe-
nyloctanediamide (SAHA-aAzide, 2). SAHA (50 mg, 0.19 mmol) in
dimethylformamide (DMF, 2 mL) was added to a solution of 5-azi-
dopentanoic acid (41 mg, 0.28 mmol), 2-chloro-1-methyl-pyridini-
um iodide (CMPI) (97 mg, 0.38 mmol), and 4-(dimethylamino)pyri-
dine (DMAP) (95 mg, 0.78 mmol) in DMF (3 mL). The reaction mix-
ture was stirred at rt for 6 h. The solvent was removed under
vacuum. The residue was dissolved in CH2Cl2, washed with water,
dried over Na2SO4, and rotary evaporated. The resulting residue
was purified by column chromatography on silica gel (CH3OH/
CH2Cl2 5:95) to give two isomers SAHA-eAzide 1 and SAHA-
aAzide 2 as white solids, 1 (10 mg, 14%) and 2 (14 mg, 20%);
1H NMR (500 MHz, CDCl3) 1: d=0.89 (t, J=7.0 Hz, 2H), 1.44 (m,
2H), 1.62–1.83 (m, 8H), 2.28 (t, J=7.0 Hz, 2H), 2.39 (t, J=7.5 Hz,
2H), 2.54 (t, J=7.5 Hz, 2H), 3.32 (t, J=6.5 Hz, 2H), 7.12 (t, J=
7.5 Hz, 1H), 7.25 (s, 1H), 7.33 (t, J=8.0 Hz, 2H), 7.53 (d, J=8.0 Hz,
2H), 9.00 ppm (s, 1H), 2: d=0.89 (t, J=7.0 Hz, 2H), 1.13 (m, 2H),
1.65–1.78 (m, 8H), 1.94 (t, J=7.0 Hz, 2H), 2.36 (t, J=7.5 Hz, 2H),
2.58 (t, J=7.5 Hz, 2H), 2.97 (s, 1H), 3.33 (t, J=6.5 Hz, 2H), 7.10 (t,
J=7.5 Hz, 1H), 7.27 (s, 1H), 7.32 (t, J=8.0 Hz, 2H), 7.52 ppm (d, J=
8.0 Hz, 2H); ESI-MS m/z [M+H]+calcd for C19H28N5O4 : 390.2, found
390.2.
Synthesis of G5-eSAHA-Alkyne 5. G5-NHAc-Alkyne 3 (10 mg,
0.31 mmol) was dissolved in CuSO4 (10 mol% per SAHA-eAzide,
1.0 mgmL¢1 H2O) and sodium ascorbate (60 mol% per SAHA-
Figure 3. Biological evaluation of the dendrimer SAHA conjugates in tumor-
associated macrophages. RAW264.7 cells treated with 1 mm free SAHA
showed significantly greater levels of apoptosis than RAW264.7 cells treated
with the dendrimer–SAHA conjugates confirming the tumor-specificity of
targeted dendrimer–SAHA conjugates. RAW264.7 cells were incubated with
dendrimer SAHA conjugates and free SAHA for 3 d and assessed for apopto-
sis using the annexin/7AAD assay. Values represent the mean  S.E.M. for
n=3 independent experiments.
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eAzide, 1.0 mgmL¢1 H2O solution) solution. SAHA-eAzide 1 (7.5
azide mole ratio to G5-NHAc-Alkyne 3, 5.0 mgmL¢1 DMSO solution)
was added. The reaction mixture was stirred at rt under N2 o/n.
Glycidol (10 mL) was added to cap the remaining free amino
groups on the dendrimer surface, and the reaction mixture was
stirred at rt for 6 h. Samples were purified using 10000 MWCO cen-
trifugal filtration devices. The purification consisted of ten cycles
(5ÕPBS and 5Õ deionized H2O) at 4800 rpm for 20 min each. The
purified dendrimer conjugates were lyophilized to yield 5 as white
solids (9.1 mg, 84%); MALDI-TOF MS m/z : 34722 [M]+ ; the 1H NMR-
integration-determined mean number of SAHA-eAzide molecules is
4.0.
Synthesis of G5-FA-eSAHA-Alkyne 6. G5-NHAc-FA-Alkyne 4
(10 mg, 0.30 mmol) was dissolved in CuSO4 (10 mol% per SAHA-
azide, 1.0 mgmL¢1 H2O) and sodium ascorbate (60 mol% per
SAHA-azide, 1.0 mgmL¢1 H2O solution) solution. SAHA-eAzide 1
(7.5 azide mole ratio to G5-NHAc-FA-Alkyne 4, 5.0 mgmL¢1 DMSO
solution) was added. The reaction mixture was stirred at rt under
N2 o/n. Excess glycidol (10 mL) was added to cap the remaining
free amino group on the dendrimer surface. The reaction mixture
was stirred at rt for an additional 6 h. Samples were purified using
10000 MWCO centrifugal filtration devices. The purification consist-
ed of ten cycles (5ÕPBS and 5Õ deionized H2O) at 4800 rpm for
20 min each. The purified dendrimer samples were lyophilized to
yield 6 as brown solids (9.1 mg, 84%); MALDI-TOF MS m/z : 35921
[M]+ ; the 1H NMR-integration-determined mean number of SAHA-
eAzide molecules is 3.2.
Cell culture: KB cells, a human cancer cell model (American Type
Culture Collection, ATCC, Manassas, USA), were maintained as
a monolayer cell culture in FA-free Roswell Park Memorial Institute
(RPMI) 1640 medium (Life Technologies, Grand Island, USA) supple-
mented with 10% fetal bovine serum (FBS), 100 UmL¢1 penicillin,
and 100 mgmL¢1 streptomycin. The cell cultures were incubated at
37 8C with 5% CO2. RAW264.7 cells were cultured at 37 8C in a hu-
midified atmosphere of 5% CO2 and 95% air, in RPMI 1640
medium containing 10% FBS supplemented with penicillin
(100 unitsmL¢1) and streptomycin (100 gmL¢1).
Apoptosis assay and flow cytometry: In preparation for flow cy-
tometry, KB cells were plated in 12-well plates and grown to 50%
confluency. Cells were washed with warm divalent cation-free PBS
(1 mL) before the addition of new medium. All cells treatments
were performed using the culture medium. After the indicated in-
cubation times, the cells were washed with warm divalent cation-
free PBS (1 mL) and immediately resuspended in culture medium,
centrifuged at 1500 rpm for 5 min, and washed with FBS-free
media. The resulting pellet was resuspended in annexin binding
buffer (100 uL, BioLegend, San Diego, USA) containing a 1:100 dilu-
tion of both stock Alexa Fluoro 647 annexin (BioLegend, San
Diego, USA) and 1 mgmL¢1 7-aminoactinomycin D (Sigma Aldrich,
St. Louis, USA) for 15 min in the dark. Cells were washed twice
with cell culture media to remove any nonspecifically bound dye,
followed by resuspending the pellet in annexin V binding buffer
(200 uL) for flow cytometric? analysis. 50000 events were collected
using an Accuri C6 Flow Cytometer (Accuri Instruments, Inc. , Ann
Arbor, USA) and analyzed using FlowJo software version 7.6.5 (Tree
Star Inc. , Ashland, USA).
Protein immunoblotting: Cells were harvested and lysed using ra-
dioimmunopreciptation assay (RIPA) buffer containing 25 mm Tris-
HCl, pH 7.6, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycho-
late, 1 mm Na3VO4 and 10 mm NaF (phosphatase inhibitors), and
0.1% SDS with 10 mL of Halt Protease Inhibitor Cocktail (Pierce,
Rockford, USA) added for each 1 mL of buffer. Samples were sepa-
rated using sodium dodecylsulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred to a polyvinylidede fluoride
(PVDF) membrane. PVDF membranes were blocked with 0.1%
BSA/0.1% Tween-20 in tris-buffered saline (TBS, blocking buffer)
and washed with blocking buffer. PVDF membranes were then
probed with rabbit antibodies against acetylated histone 3 (1:500
for 1 h) or total extracellular-signal-regulated kinase 1 (ERK1, 1:1000
for 1 h, Santa Cruz Biotechnology; Santa Cruz, USA). Alkaline-phos-
phatase-conjugated goat anti-rabbit secondary antibodies (Thermo
Scientific, Waltham, USA) were used at a dilution of 1:20000 and in-
cubated for 1 h.
Statistics: Data were analyzed by Student’s t-test using GraphPad
6.01 statistical software (GraphPad Software Inc. , San Diego, USA).
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